Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Cancer Res. 2015 Apr 13;75(12):2489–2500. doi: 10.1158/0008-5472.CAN-14-3167

Figure 1. RAS-MAPK signaling inhibition by selumetinib in EGFR inhibitor resistant cell lines.

Figure 1

(A, B) Cells cultured in the presence or absence of originating EGFR inhibitor as indicated were dosed with titrations of selumetinib for 6 hours. Lysates were analysed by immunoblotting. Data is representative of 2 separate experiments. (C) WZR_1 cells cultured in the absence of WZ4002 prior to the experiment were treated with titrations of selumetinib over 96 hours with no added WZ4002, 0.03 μM or 0.3 μM WZ4002. Data is representative of two separate experiments.